BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
CytoDyn Inc. CYDY
19 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2022 · Revenue 0.0 · Net income -79.8
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2016 · ROE -566.1%
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | 0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | · | · | −0.0 | −0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.0 | 0.0 | −0.0 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | · | · | · |
| EPS, diluted $ | −0.03 | 0.00 | −0.05 | −0.10 | −0.31 | −0.30 | −0.33 | · | · | · | · | · | · | · | · | · | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | −566.1 | · | · | −672.3 | · | · | · | · | · | · |
| Shares out B | 1.37 | 1.25 | 1.06 | 0.92 | 0.72 | 0.63 | 0.52 | 0.33 | 0.22 | 0.15 | 0.12 | 0.06 | 0.06 | 0.03 | 0.03 | 0.02 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 37 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsMay 31
SEC categorysmaller reporting company
Data on record since2007